胆囊后三角解剖入路与胆囊前三角解剖入路腹腔镜胆囊切除术治疗胆囊结石患者手术效果比较研究*

doi:10.3969/j.issn.1672-5069.2025.05.036

Abstract

Abstract: Objective The purpose of this study was to compare laparoscopic cholecystectomy (LC) by through posterior Calot’ s triangle approach (PCTA) or through anterior Calot’ s triangle approach (ACTA) in dealing with patients with cholecystolithiasis and chronic cholecystitis. Methods 197 patients with cholecystolithiasis and chronic cholecystitis were encountered in our hospital between June 2021 and June 2024, and all underwent LC surgery. For the operation, by through PCTA in 96 cases, and by through ACTA in 101 cases. Visual analogue scale (VAS) was evaluated for postoperative pain. Serum C-reactive protein level was detected by immunoturbidimetry, serum interleukin (IL)-6 and tumor necrosis factor (TNF)-α were detected by ELISA, plasma superoxide dismutase (SOD) level was detected by ammonium phosphate method, plasma glutathione peroxidase (GSH-Px) level was detected by DTNB direct color development, and plasma malondialdehyde (MDA) level was assayed by thiobarbituric acid. Results Surgical time and postoperative exhaust time in PCTA group were(33.6±7.3)min and (22.3±5.6)h, both much shorter than [(39.1±7.1) minand (28.8±6.1)h, respectively, P<0.05], and operational bleeding was (36.9±11.4)mL, much less than [(49.5±12.9)mL, P<0.05] in ACTA group; by end of three days, VAS score in PCTA group was (2.5±0.4)points, much lower than [(3.1±0.5)points, P<0.05] in ACTA group; by 24 h, serum IL-6, IL-8, TNF-α and CRP levels in PCTA group were (12.1±2.0)ng/L, (17.3±2.7)ng/L, (19.5±2.7)ng/L and (18.3±1.6)mg/L, all significantly lower than [(15.2±1.4)ng/L, (22.7±3.1)ng/L, (23.6±3.5)ng/L and (29.1±1.1)mg/L, respectively, P<0.05] in ACTA group; serum SOD level was (121.0±18.4)U/ml, much higher than [(105.3±19.2)U/ml, P<0.05]in ACTA group. Conclusion For LC operation, by through PCTA could be relatively easy, which might cost less operational time and induce less body inflammatory and oxidative stress.

Key words: Cholecystolithiasis, Chronic cholecystitis, Laparoscopic cholecystectomy, Posterior Calot’ s triangle approach, Therapy

Zhang Wenjie, Zhou Lichen, Liu Yu, et al. Comparison of laparoscopic cholecystectomy by through posterior Calot’ s triangle approach or through anterior Calot’ s triangle approach in dealing with patients with cholecystolithiasis and chronic cholecystitis[J]. Journal of Practical Hepatology, 2025, 28(5): 784-787.

References

[1] Ramírez-Giraldo C, Isaza-Restrepo A, Rico-Rivera EX, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute calculous cholecystitis in patients over 90 years of age. Langenbecks Arch Surg, 2023, 408(1):194-194.
[2] Xia Z, Liu Y, Sun S, et al. The value of preoperative neutrophil/lymphocyte ratio in predicting the severity of cholecystolithiasis with cholecystitis in elderly patients.BMC Surg, 2023, 23(1):360-360.
[3] Zeindler J, Hess GF, Sedlaczek P, et al. Preoperative MRCP is not associated with lower complication rates but shorter hospital stay in laparoscopic cholecystectomy. Br J Surg, 2024, 111(3):35-50.
[4] 罗登,赖习华,刘首记.腹腔镜胆囊切除术治疗胆囊结石伴慢性胆囊炎患者治疗效果分析.实用肝脏病杂志,2021,24(2):276-279.
[5] Mangiavillano B, Calabrese F, Auriemma F,et al.Symptomatic cholelithiasis and acute cholecystitistreated by EUS-guided gallbladder drainage with gallbladder toilette. Endoscopy, 2023, 55(S 01):E284-E285.
[6] Kondo M, Hagiwara K, Nukaya A,et al. Laparoscopic cholecystectomy using the subserosal layer dissection technique in dogs: 34 cases (2015‐2021). J Small Anim Pract, 2023, 64(4):288-295.
[7] 中华消化杂志编辑委员会,中华医学会消化病学分会肝胆疾病协作组.中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2018年).中华消化杂志,2019,39(2):73-79.
[8] Faiz KW. VAS-visuell analog skala. Tidsskr Nor Laegeforen, 2014, 134(3):323-323.
[9] Ignjatovic MK, Lukic D, Dermanovic MPM.Hepatolithiasis followed by recurrent cholangitis as a consequence of inadequate hepaticojejunostomy for common bile duct injury. Srp Arh Celok Lek, 2022, 150(11-12):707-711.
[10] Firat YD, Idiz UO, Cakir C,et al.Prospective multi-center study of surgeon's assessment of the gallbladder compared to histopathological examination to detect incidental malignancy. Langenbecks Arch Surg, 2020, 404(5):573-579.
[11] Gumusoglu AY, Kabuli HA, Kones O,et al.What is the treatment role of transpapillary cholecystostomy for delayed cholecystectomy in the coexistence of acute cholecystitis and cholangitis. Surg Laparosc Endosc Percutan Tech, 2020, 31(1):71-75.
[12] Gupta RA, Pokharia P, Khanduri A. Laparoscopic treatment of duplicate gallbladder with acute cholecystitis. J Minim Access Surg, 2020, 16(4):447-448.
[13] 李海东,徐安安,王波,等.经脐单孔腹腔镜胆囊切除术治疗慢性胆囊炎合并胆囊结石.中华肝胆外科杂志,2019,25(10):733-736.
[14] 徐元,章波.吲哚青绿近红外荧光胆道造影指导腹腔镜胆囊切除术治疗胆囊结石患者疗效研究.实用肝脏病杂志,2024,27(1):141-144.
[15] Latenstein CSS, Hannink G, van der Bilt JDW, et al.A clinical decision tool for selection of patients with symptomatic cholelithiasis for cholecystectomy based on reduction of pain and a pain-free state following surgery.JAMA Surg, 2021, 156(10):e213706.
[16] Ostlie DJ, Juang OO, Iqbal CW,et al.Single incision versus standard 4-port laparoscopic cholecystectomy: A prospective randomized trial. J Pediatr Surg, 2013, 48(1):209-214.
[17] Lai W, Xu N, Lin W,et al.Magnetic resonance imaging can minimize the missed diagnosis of bile duct stones caused by only ultrasound scan before cholecystectomy. Asian J Surg, 2022, 45(12):2923-2924.
[18] Omar MA, Kamal A, Redwan A, et al. Post-cholecystectomy major bile duct injury: ideal time to repair based on a multicentre randomized controlled trial with promising results. Int J Surg, 2023, 109(5):1208-1221.
[19] Wang Y, Chen XP. Comparison of the effects of ampulla-guided realignment and conventional gallbladder triangle anatomy in difficult laparoscopic cholecystectomy. Langenbecks Arch Surg, 2023, 409(1):17.
[20] Cai H, Gao P, Lu F, et al. Laparoscopic transduodenal ampullectomy: how we have standardized the technique (with video). Ann Surg Oncol, 2023, 30(2):1156-1157.
[21] Hung YL, Chen HW, Tsai CY, et al.The optimal timing of interval laparoscopic cholecystectomy following percutaneous cholecystostomy based on pathological findings and the incidence of biliary events. J Hepatobiliary Pancreat Sci, 2021, 28(9):751-759.

Comparison of laparoscopic cholecystectomy by through posterior Calot’ s triangle approach or through anterior Calot’ s triangle approach in dealing with patients with cholecystolithiasis and chronic cholecystitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cong Dongwei, Liu Lina, Gao Wenjuan, et al. Antiviral efficacy of pegylated interferon α-2b and entecavir or tenofovir in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 655-658.
[2]	Chen Wenzhe, Wang Qingyuan, Chen Tian, et al. Impact of apolipoprotein B gene polymorphisms on response to pegylated interferon alpha-2b treatment in patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 659-662.
[3]	Yuan Ling, Jiang Xia, Sun Meijie. Clinical efficacy of tenofovir amibufenamide and tenofovir alafenamide fumarate in rescue treatment of ETV-treated patients with chronic hepatitis B and low-level viremia [J]. Journal of Practical Hepatology, 2025, 28(5): 667-670.
[4]	Tang Qin, Hua Zhong, Su Qilin, et al. A preliminary study on efficacy of tenofovir amibufenamide and Biejiajian pill combination in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 671-674.
[5]	Hao Shuai, Wang Ziyi, Zhang Xinyi, et al. Normalized follow-up for hepatitis C micro-elimination strategy in a general tertiary hospital [J]. Journal of Practical Hepatology, 2025, 28(5): 675-678.
[6]	Liu Zhidong, Li Wensong, Gao Zhen, et al. Efficacy of daclatasvir and asunaprevir in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(5): 679-682.
[7]	Xin Wenyuan, Li Yuwei, Wu Jun. Efficacy of dalatavir combination with asulivir in the treatment of patients with chronic hepatitis C with genotype 1b infection [J]. Journal of Practical Hepatology, 2025, 28(5): 683-686.
[8]	Zhang Lei, Wang Yaru, Li Huiping, et al. Clinical observation of semaglutide and metformin combination in treatment of patients with type 2 diabetes mellitus and concomitant nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(5): 699-702.
[9]	Wang Xia, DuanWangwang, Li Menghui. Application of exenatide at base of oral polyenephosphatidylcholine in treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2025, 28(5): 715-718.
[10]	Liu Lihua, You Xiaohong, Fan Zhouhong. Combination of polyene phosphatidylcholine and silybin in treatment of patients with drug-induced liver injury: An analysis of 102 cases [J]. Journal of Practical Hepatology, 2025, 28(5): 723-726.
[11]	Zhu Yingjing, Wu Jie, Tian Xinyue, et al. Endoscopic tissue glue injection and esophageal variceal ligation in treatment of patients with hepatitis B-induced liver cirrhosis and esophageal and gastric varices bleeding [J]. Journal of Practical Hepatology, 2025, 28(5): 731-734.
[12]	Chen Jie, Yang Caimin, Peng Cailing, et al. Evaluation of histological changes based on Beijing standard in patients with hepatitis B-induced liver cirrhosis during entecavir antiviral therapy [J]. Journal of Practical Hepatology, 2025, 28(5): 735-738.
[13]	Mu Ya, Ge Naijian, Liu Xue, et al. Clinical efficacy of bevacizumab and sintilimab combination after TACE in the treatment of patients with unresectable hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 751-754.
[14]	Zhang Xiaozhao, Lei Kai, Qi Yabin, et al. Attilizumab and targeting and immune checkpoint inhibitor combination after TACE in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(5): 759-762.
[15]	Xu Jia, Peng Weiwei, Yin Na, et al. Clinical observation of sintilimab and anti-vascular endothelial growth factor antibody in the treatment of patients with unresectable hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 763-766.